Cogent Biosciences, Inc. Cogent Biosciences, Inc.

Cogent Biosciences, Inc.

COGT

Peringkat dalam Saham #3347
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted... Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Harga Saham
$30.08
Kapitalisasi Pasar
$5.22B
Perubahan (1 hari)
1.90%
Perubahan (1 tahun)
83.53%
Negara
US
Perdagangan Cogent Biosciences, Inc. (COGT)

Kategori

Healthcare
EPS untuk Cogent Biosciences, Inc. (COGT)
EPS per June 2026 TTM: $-2.31
Menurut laporan keuangan terbaru dan harga saham Cogent Biosciences, Inc., EPS perusahaan saat ini (TTM) adalah $-2.31. Pada akhir 2023, perusahaan memiliki EPS sebesar $-2.42 peningkatan dibandingkan EPS tahun 2022 sebesar $-2.26.
Riwayat EPS untuk Cogent Biosciences, Inc. dari 2015 hingga 2026
EPS di akhir setiap tahun
Tahun EPS Mengubah
2026 (TTM) $-2.31 -6.10%
2024 $-2.46 1.65%
2023 $-2.42 7.08%
2022 $-2.26 22.16%
2021 $-1.85 -69.17%
2020 $-6.00 51.13%
2019 $-3.97 -28.47%
2018 $-5.55 60.87%
2017 $-3.45 11.29%
2016 $-3.10 174.34%
2015 $-1.13 0.00%
EPS untuk perusahaan sejenis atau pesaing
Perusahaan EPS Perbedaan EPS Negara
$17.32 -849.78%
US
$-7.98 245.45%
US
$-5.29 129.00%
AU
- -
CH
$27.74 -1,300.87%
NL